NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,557.74 mln
Float82.41 mln
Earnings Date07/09/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-2.45
Borderline
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.12
Very low leverage
ROE
-63.63
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Nurix Therapeutics is a clinical-stage drug development company working on new treatments for cancer, autoimmune disorders, and other serious diseases. The company specializes in small molecule drugs that work by breaking down specific proteins that drive illness, with several candidates currently being tested in clinical trials. Nurix works alongside major pharmaceutical partners including Gilead Sciences, Sanofi, and Pfizer to advance its pipeline toward patients. Founded in 2009 and based in Brisbane, California, the company is building on a growing body of research to bring next-generation therapies to market.
